Home
ARQT
ARQT News

Latest Arcutis Biotherapeutics Inc. (ARQT) News on November 21, 2024

Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average

Zacks

a day ago

Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average

Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors

Zacks

a day ago

Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors

Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now

Zacks

2 days ago

Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now

Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average

Zacks

2 days ago

Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average

Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour

GlobeNewswire

8 days ago

Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour

Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?

Zacks

10 days ago

Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?

Arcutis Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

13 days ago

Arcutis Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations

Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ...

GuruFocus.com

14 days ago

Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ...

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates

Zacks

15 days ago

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

15 days ago

Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

High Growth Tech Stocks In The United States To Watch

Simply Wall St.

15 days ago

High Growth Tech Stocks In The United States To Watch

Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 Result

GuruFocus.com

16 days ago

Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 Result

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

17 days ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks

24 days ago

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Zacks

a month ago

Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting

GlobeNewswire

a month ago

Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

GlobeNewswire

a month ago

Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

MT Newswires

a month ago

Arcutis Biotherapeutics' Zoryve Approved to Treat Seborrheic Dermatitis in Canada

Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis

Pharmaceutical Technology

a month ago

Health Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitis

Arcutis Canada Announces Health Canada Approval of ZORYVE® Foam to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

CNW Group

a month ago

Arcutis Canada Announces Health Canada Approval of ZORYVE® Foam to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

MT Newswires

a month ago

Arcutis Biotherapeutics Receives Approval in Canada for Skin Disease Cream Zoryve

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

GlobeNewswire

a month ago

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

Arcutis Biotherapeutics, Inc (ARQT): A Small-Cap Leader in Skin Disease Treatments

Insider Monkey

a month ago

Arcutis Biotherapeutics, Inc (ARQT): A Small-Cap Leader in Skin Disease Treatments

Zoryve Drives Revenue Growth at Arcutis Biotherapeutics, Inc. (ARQT)

Insider Monkey

a month ago

Zoryve Drives Revenue Growth at Arcutis Biotherapeutics, Inc. (ARQT)

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Exploring High Growth Tech Stocks In The US October 2024

Simply Wall St.

2 months ago

Exploring High Growth Tech Stocks In The US October 2024

New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

GlobeNewswire

2 months ago

New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

MT Newswires

2 months ago

Arcutis Biotherapeutics Says US FDA Accepts Supplemental New Drug Application for Psoriasis Treatment

FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

GlobeNewswire

2 months ago

FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

MT Newswires

2 months ago

Arcutis Biotherapeutics Says Phase 3 Data Confirm Zoryve's Efficacy in Atopic Dermatitis

Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

GlobeNewswire

2 months ago

Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology

Insider Selling: Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT)

GuruFocus.com

2 months ago

Insider Selling: Director Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255

GlobeNewswire

3 months ago

Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255

Arcutis Biotherapeutics, Inc. (ARQT): This Small-Cap Healthcare Stock Is A Good Buy Right Now

Insider Monkey

3 months ago

Arcutis Biotherapeutics, Inc. (ARQT): This Small-Cap Healthcare Stock Is A Good Buy Right Now

GlobeNewswire

3 months ago

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

MT Newswires

3 months ago

Jefferies Initiates Arcutis Biotherapeutics at Buy

Exploring Three High Growth Tech Stocks In The United States

Simply Wall St.

3 months ago

Exploring Three High Growth Tech Stocks In The United States

Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

GlobeNewswire

3 months ago

Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Thomson Reuters StreetEvents

3 months ago

Q2 2024 Arcutis Biotherapeutics Inc Earnings Call

CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

3 months ago

CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates

Zacks

3 months ago

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Misses Revenue Estimates

MT Newswires

3 months ago

Arcutis Biotherapeutics Q2 Loss Narrows, Revenue Rises

Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

3 months ago

Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long

Simply Wall St.

3 months ago

Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long

Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know

Zacks

3 months ago

Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024

GlobeNewswire

4 months ago

Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024

Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last?

Zacks

4 months ago

Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last?

MT Newswires

4 months ago

Arcutis Biotherapeutics Signs Co-Promote Deal for Zoryve With Kowa Pharmaceuticals; Shares Down

Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.

GlobeNewswire

4 months ago

Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.

Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

GlobeNewswire

4 months ago

Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis

MT Newswires

4 months ago

Arcutis Biotherapeutics Submits Supplemental New Drug Application to US FDA for Psoriasis Treatment

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

GlobeNewswire

4 months ago

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

GlobeNewswire

4 months ago

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?

Zacks

4 months ago

Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?

Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why

Zacks

4 months ago

Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why

Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data

Zacks

4 months ago

Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data

Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals

Zacks

4 months ago

Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals

Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why

Zacks

4 months ago

Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why

Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan

Zacks

4 months ago

Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan

Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK

Zacks

4 months ago

Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK

Arcutis bags FDA approval for atopic dermatitis cream after delay

Pharmaceutical Technology

4 months ago

Arcutis bags FDA approval for atopic dermatitis cream after delay

Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View

Zacks

4 months ago

Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View

FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years

Benzinga

4 months ago

FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years

AbbVie names new R&D head; Arcutis eczema cream approved

BioPharma Dive

4 months ago

AbbVie names new R&D head; Arcutis eczema cream approved

MT Newswires

4 months ago

Arcutis Biotherapeutics' Zoryve Gets US FDA Approval for Atopic Dermatitis

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

GlobeNewswire

4 months ago

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis

GlobeNewswire

4 months ago

Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Investor's Business Daily

5 months ago

Cheap Stocks To Buy: This Microcap Gold Stock Breaks Out

FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease

Zacks

5 months ago

FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease

FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma

Zacks

5 months ago

FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma

AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer

Zacks

5 months ago

AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer

FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder

Zacks

5 months ago

FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder

OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies

Zacks

5 months ago

OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?

Zacks

5 months ago

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?

Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 99.89%: Read This Before Placing a Bet

Zacks

5 months ago

Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 99.89%: Read This Before Placing a Bet

Avidity (RNA) Up 33% on Rare Muscle Disease Study Results

Zacks

5 months ago

Avidity (RNA) Up 33% on Rare Muscle Disease Study Results

FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D

Zacks

5 months ago

FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D

Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why

Zacks

5 months ago

Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why

Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug

Zacks

5 months ago

Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug

MT Newswires

5 months ago

Sector Update: Health Care Stocks Mixed Premarket Tuesday

MT Newswires

5 months ago

Arcutis Biotherapeutics Says Experimental Cream Showed Improvements in Atopic Dermatitis Symptoms

Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

GlobeNewswire

5 months ago

Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease

Zacks

5 months ago

Amgen's (AMGN) Uplizna Meets Study Goal for Rare Disease

AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug

Zacks

5 months ago

AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

GlobeNewswire

6 months ago

Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study

Zacks

6 months ago

Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study

Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire

6 months ago

Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?

Zacks

6 months ago

Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?

J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms

Zacks

6 months ago

J&J's (JNJ) Oral Pill Improves Depression & Insomnia Symptoms

Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty

Zacks

6 months ago

Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty

Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data

Zacks

6 months ago

Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data

Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why

Zacks

6 months ago

Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why

Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data

Zacks

6 months ago

Merus (MRUS) Surges 36% on Head & Neck Cancer Antibody Data

Iovance (IOVA) Up 5% on Updated Data From Melanoma Study

Zacks

6 months ago

Iovance (IOVA) Up 5% on Updated Data From Melanoma Study

Analysts Are Betting On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) With A Big Upgrade This Week

Simply Wall St.

6 months ago

Analysts Are Betting On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) With A Big Upgrade This Week

Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027

Zacks

6 months ago

Pfizer (PFE) Starts Another Cost-Cut Plan to Save $1.5B by 2027

Share on Social Networks: